A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis

Machiels, J.-P., Wülfing, C., Richel, D. J., Beuzeboc, P., Garcia Del Muro, X., Grimm, M.-O., Farrell, J., Colman, J. R., & El-Harity, I. A. (2004). A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis. Journal of Clinical Oncology, 22(14), 410S. https://hdl.handle.net/2078.5/140771 (Original work published 2004)